Go Pro
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

Becton, Dickinson and Company logo
$190.58 -1.42 (-0.74%)
Closing price 03:59 PM Eastern
Extended Trading
$191.25 +0.67 (+0.35%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Becton, Dickinson and Company Stock (NYSE:BDX)

Advanced

Key Stats

Today's Range
$190.35
$193.07
50-Day Range
$140.37
$191.95
52-Week Range
$127.59
$193.07
Volume
1.31 million shs
Average Volume
2.65 million shs
Market Capitalization
$52.51 billion
P/E Ratio
57.40
Dividend Yield
2.20%
Price Target
$185.67
Consensus Rating
Hold

Company Overview

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business. In diagnostics and life sciences, the company supplies specimen collection systems, diagnostic instrument platforms, molecular and microbiology testing systems, reagents and consumables, and laboratory automation and analytics tools that support clinical testing and biomedical research.

Founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, BD has grown through organic development and strategic acquisitions to become a multinational supplier to the healthcare sector. A notable expansion of its interventional device capabilities followed the acquisition of C.R. Bard, broadening BD’s offerings in vascular, urology and oncology procedural products. The company is headquartered in New Jersey and operates globally, serving customers across North America, Europe, Asia Pacific, Latin America and other regions through a combination of direct sales and distribution partners.

BD is led by President and Chief Executive Officer Thomas E. Polen, and its organization is structured to support innovation, regulatory compliance and global supply chains that deliver products to hospitals, clinics, research laboratories and life science companies. The company emphasizes product safety, clinician and patient protection, and solutions that support clinical workflows and diagnostic decision-making.

AI Generated. May Contain Errors.

Becton, Dickinson and Company Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

BDX MarketRank™: 

Becton, Dickinson and Company scored higher than 71% of companies evaluated by MarketBeat, and ranked 196th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Becton, Dickinson and Company has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on no strong buy ratings, 8 buy ratings, 8 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Becton, Dickinson and Company is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Becton, Dickinson and Company has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Becton, Dickinson and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Becton, Dickinson and Company are expected to grow by 4.50% in the coming year, from $12.67 to $13.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Becton, Dickinson and Company is 57.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Becton, Dickinson and Company is 57.40, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.39.

  • Price to Earnings Growth Ratio

    Becton, Dickinson and Company has a PEG Ratio of 13.53. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Becton, Dickinson and Company has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Becton, Dickinson and Company's valuation and earnings.
  • Percentage of Shares Shorted

    3.65% of the float of Becton, Dickinson and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Becton, Dickinson and Company has a short interest ratio ("days to cover") of 5.73.
  • Change versus previous month

    Short interest in Becton, Dickinson and Company has recently decreased by 3.53%, indicating that investor sentiment is improving.
  • Dividend Yield

    Becton, Dickinson and Company pays a meaningful dividend of 2.19%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Becton, Dickinson and Company has been increasing its dividend for 53 years.

  • Dividend Coverage

    The dividend payout ratio of Becton, Dickinson and Company is 126.51%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 31.72% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

  • Read more about Becton, Dickinson and Company's dividend.
  • News Sentiment

    Becton, Dickinson and Company has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 33 news articles for Becton, Dickinson and Company this week, compared to 8 articles on an average week.
  • Search Interest

    18 people have searched for BDX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Becton, Dickinson and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,974,669.00 in company stock.

  • Percentage Held by Insiders

    0.40% of the stock of Becton, Dickinson and Company is held by insiders.

  • Percentage Held by Institutions

    86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Becton, Dickinson and Company's insider trading history.
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDX Stock News Headlines

It’s not about Greenland
The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.tc pixel
See More Headlines

BDX Stock Analysis - Frequently Asked Questions

Becton, Dickinson and Company's stock was trading at $194.11 at the start of the year. Since then, BDX shares have decreased by 1.8% and is now trading at $190.5840.

Becton, Dickinson and Company (NYSE:BDX) released its earnings results on Thursday, August, 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company's quarterly revenue was up 5.4% compared to the same quarter last year.
Read the conference call transcript
.

Becton, Dickinson and Company's Board of Directors authorized a share buyback plan on Tuesday, January 27th 2026, which allows the company to repurchase $10,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 0% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board of directors believes its shares are undervalued.

Becton, Dickinson and Company subsidiaries include these companies: Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and more.

Becton, Dickinson and Company's top institutional shareholders include California State Teachers Retirement System (25.37%), BlackRock Inc. (8.93%), Wellington Management Group LLP (2.31%) and Bank of America Corp DE (1.14%). Insiders that own company stock include Thomas E Polen Jr, Bertram L Scott, Claire Fraser, Michael Feld, Shana Carol Neal, Roland Goette, Michael David Garrison, Jeffrey William Henderson, Richard Byrd, Richard Byrd, David Shan and Thomas J Spoerel.
View institutional ownership trends
.

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ExxonMobil (XOM), Broadcom (AVGO), AbbVie (ABBV) and Chevron (CVX).

Company Calendar

Record date for 6/30 Dividend
6/09/2026
Ex-Dividend for 6/30 Dividend
6/09/2026
Dividend Payable
6/30/2026
Last Earnings
8/06/2026
Today
8/24/2026
Record date for 9/30 Dividend
9/09/2026
Ex-Dividend for 9/30 Dividend
9/09/2026
Dividend Payable
9/30/2026
Fiscal Year End
9/30/2026
Next Earnings (Estimated)
11/05/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:BDX
CIK
10795
Employees
72,000
Year Founded
1897

Price Target and Rating

High Price Target
$210.00
Low Price Target
$150.00
Potential Upside/Downside
-2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.32
Trailing P/E Ratio
57.40
Forward P/E Ratio
15.04
P/E Growth
13.53
Net Income
$1.68 billion
Net Margins
4.52%
Pretax Margin
8.59%
Return on Equity
14.79%
Return on Assets
6.93%

Debt

Debt-to-Equity Ratio
0.55
Current Ratio
0.87
Quick Ratio
0.51

Sales & Book Value

Annual Sales
$21.84 billion
Price / Sales
2.40
Cash Flow
$22.91 per share
Price / Cash Flow
8.32
Book Value
$88.58 per share
Price / Book
2.15

Miscellaneous

Outstanding Shares
275,540,000
Free Float
274,438,000
Market Cap
$52.51 billion
Optionable
Optionable
Beta
0.19

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:BDX) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners